DEFERASIROX - search results

pharmacor pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: hydrogenated castor oil; poloxamer; crospovidone; sodium hydroxide; povidone; microcrystalline cellulose; colloidal anhydrous silica; sodium stearylfumarate; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor deferasirox fc deferasirox 90 mg film-coated tablet blister pack

pharmacor pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: crospovidone; sodium stearylfumarate; hydrogenated castor oil; colloidal anhydrous silica; poloxamer; povidone; sodium hydroxide; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

akm deferasirox fc deferasirox 180 mg film-coated tablet bottle

pharmacor pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; colloidal anhydrous silica; sodium hydroxide; sodium stearylfumarate; hydrogenated castor oil; poloxamer; crospovidone; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

akm deferasirox fc deferasirox 90 mg film-coated tablet bottle

pharmacor pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; microcrystalline cellulose; sodium stearylfumarate; crospovidone; hydrogenated castor oil; poloxamer; sodium hydroxide; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.